1. Home
  2. DSM vs PGEN Comparison

DSM vs PGEN Comparison

Compare DSM & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BNY Mellon Strategic Municipal Bond Fund Inc.

DSM

BNY Mellon Strategic Municipal Bond Fund Inc.

HOLD

Current Price

$6.16

Market Cap

301.5M

Sector

Finance

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.26

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSM
PGEN
Founded
1989
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.5M
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DSM
PGEN
Price
$6.16
$4.26
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.67
AVG Volume (30 Days)
161.7K
5.1M
Earning Date
01-01-0001
11-13-2025
Dividend Yield
3.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,309,000.00
Revenue This Year
N/A
$342.78
Revenue Next Year
N/A
$478.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
59.20
52 Week Low
$4.69
$0.76
52 Week High
$6.05
$5.23

Technical Indicators

Market Signals
Indicator
DSM
PGEN
Relative Strength Index (RSI) 68.27 55.59
Support Level $5.97 $4.05
Resistance Level $6.05 $4.53
Average True Range (ATR) 0.05 0.29
MACD 0.01 0.04
Stochastic Oscillator 85.42 71.23

Price Performance

Historical Comparison
DSM
PGEN

About DSM BNY Mellon Strategic Municipal Bond Fund Inc.

BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: